Evolent Health (EVH) Cash from Financing Activities (2015 - 2026)

Evolent Health's Cash from Financing Activities history runs 12 years deep, the most recent figure standing at -$4.0 million for Q1 2026.

• On a quarterly basis, Cash from Financing Activities fell 103.68% year-over-year to -$4.0 million in Q1 2026; TTM through Mar 2026 was -$147.8 million, a 259.89% decrease from a year earlier, with the FY2025 full-year figure at -$35.9 million, down 6258.23% from the prior year.
• Cash from Financing Activities rose to -$4.0 million in Q1 2026 per EVH's latest filing, from -$93.0 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $379.7 million in Q1 2023 and bottomed at -$103.4 million in Q2 2024.
• The 5-year median for Cash from Financing Activities is -$8.9 million (2025), against an average of $21.9 million.
• Across the five-year window, Cash from Financing Activities surged 26901.72% in 2022 and tumbled 677.15% in 2023, its largest moves.
• Year by year, Cash from Financing Activities stood at -$10.9 million in 2022, then tumbled by 677.15% to -$84.4 million in 2023, then jumped by 214.93% to $96.9 million in 2024, then slumped by 195.97% to -$93.0 million in 2025, then surged by 95.73% to -$4.0 million in 2026.
• Per Business Quant, the three latest EVH Cash from Financing Activities figures stand at -$4.0 million (Q1 2026), -$93.0 million (Q4 2025), and -$41.8 million (Q3 2025).